GET DAILY SIGNALSAbbVie (ABBV) Delivers +10.3% Revenue Growth in Q3 2026 Earnings
Key Takeaways
- AbbVie reported third-quarter 2026 worldwide net revenues of $17.404 billion, up 10.3% year over year and slightly above Wall Street's consensus of roughly $17.36 billion.
- Adjusted diluted earnings per share (EPS) came in at $3.82, ahead of the consensus estimate of about $3.74, while GAAP diluted EPS reached $2.37.
- Immunology led the beat, with Skyrizi sales of about $5.78 billion and Rinvoq sales of about $2.71 billion more than offsetting a 31.2% decline in legacy blockbuster Humira.
- AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $13.95 to $13.99 and announced a 5.2% dividend increase to $1.82 per share.
- Aesthetics remained the main soft spot, while oncology growth stayed subdued as Imbruvica continued to decline.
- For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast pages dedicated to ABBV.
- Discover additional market opportunities by exploring Trending AI Robots.
Putting the Results in Context
AbbVie's third-quarter 2026 results represent another step in the company's ongoing shift away from Humira, its former flagship immunology product now facing ongoing biosimilar pressure. I have been watching closely to see whether Skyrizi and Rinvoq can scale quickly enough to offset that decline, and this quarter provided clear evidence that they can. Momentum in immunology and neuroscience, along with the raised full-year outlook and dividend hike, shows management feels confident about the path ahead. At the same time, the numbers underscore persistent challenges in aesthetics and oncology.
Breaking Down the Reported Figures
AbbVie recorded worldwide net revenues of $17.404 billion for the quarter ended September 30, 2026, a 10.3% increase from $15.776 billion a year earlier and modestly above the consensus near $17.36 billion. GAAP diluted EPS rose to $2.37 from $0.10 in the prior-year period, while adjusted diluted EPS reached $3.82, roughly double the $1.86 posted last year and ahead of the $3.74 consensus. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
Immunology revenue climbed 16.3% to $9.165 billion, driven by Skyrizi (roughly $5.78 billion, up about 23%) and Rinvoq (about $2.71 billion, up nearly 24%). Humira dropped 31.2% to $683 million. Neuroscience revenue grew 19.4% to $3.389 billion, with Vraylar exceeding $1.07 billion. Oncology edged up 0.8% to $1.696 billion, while aesthetics slipped 1.4% to $1.176 billion. Net income attributable to AbbVie surged to $4.218 billion from $186 million a year ago.
Management lifted full-year 2026 adjusted diluted EPS guidance to $13.95 to $13.99 from the prior $13.76 to $13.96 range and raised full-year revenue guidance by $200 million. The company also declared a quarterly dividend of $1.82 per share, representing a 5.2% increase.
Initial Market Reaction
The market response was mixed. While adjusted EPS and revenue both came in ahead of expectations, the raised full-year guidance midpoint of roughly $13.97 aligned closely with existing estimates, limiting upside potential. Shares traded flat to modestly lower in early trading in some reports, though others noted improving sentiment tied to the dividend increase and continued immunology strength. Overall, the results support the view that AbbVie's post-Humira strategy remains on track, even as softness in aesthetics and oncology warrants continued attention.
What to Watch Going Forward
Investors should monitor whether Skyrizi and Rinvoq maintain their double-digit growth, especially as new indications for Rinvoq in vitiligo and alopecia areata move toward potential U.S. approvals. Management sees these two products contributing nearly $2 billion in peak sales, making their commercial progress an important catalyst.
The aesthetics segment needs watching as well. Botox Cosmetic showed modest growth, but Juvéderm continued to decline amid softer consumer spending. Signs of stabilization and new product launches could support a gradual rebound. In oncology, pipeline developments such as potential approvals for etentamig in multiple myeloma and Epkinly in frontline DLBCL stand out as 2027 catalysts. The Apogee Therapeutics acquisition adds further immunology and respiratory assets to track. Updated guidance, dividend trends, and any fourth-quarter IPR&D charges will also shape the outlook into 2027.
Enhancing Research with AI Tools
In my own analysis, I frequently rely on Tickeron's AI Screener to quickly filter stocks by technical patterns, fundamentals, and AI-driven signals. It helps surface comparable names in the sector and refine trade ideas without spending hours on manual screening. This approach keeps my workflow efficient while staying focused on the data that matters most for names like ABBV.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 52 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 213 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-87.802) is very low in comparison to the industry average of (-1.403). ABBV has a moderately high P/E Ratio (83.302) as compared to the industry average of (21.451). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.039) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement